Robert H. Vonderheide

Robert H. Vonderheide, MD, DPhil, is a Professor in the Department of Medicine at the University of Pennsylvania Perelman School of Medicine. He serves as Director of the Abramson Cancer Center and Abramson Family Cancer Research Institute, along with roles as Vice Dean for Cancer Programs at Penn Medicine and Vice President for Cancer Programs at the Penn Health System.

• Education: BSc in Chemical Engineering (University of Notre Dame, 1985), DPhil in Immunology (Oxford University, 1989), MD (Harvard Medical School, 1993)
• Research Focus: Tumor immunology, antigen optimization, immuno-suppressive tumor microenvironment, and clinical translation of vaccines/antibodies for pancreatic cancer, breast cancer, and melanoma

Key Research Themes: His lab investigates CD40 regulation, GM-CSF/PD-1/CTLA-4 pathways, and immune surveillance through genetically engineered mouse models. Clinical work includes Phase I/II trials of novel immunotherapies.

Article Trends: 2021 publications span pancreatic cancer (CD40 agonists, PARP inhibitors), melanoma (radiotherapy combinations), hematologic malignancies (CD8+ T cell responses in COVID-19), and glioblastoma (IL-6/CD40 dual targeting).

Lab Personnel: Includes Graduate Students (PhD/MD-PhD programs), Post-doctoral Scholars, and Administrators. Collaborations with institutions like the Abramson Family Cancer Research Institute and Penn Blood Disorders Center are highlighted.